Track CRSP and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Create a free account to build watchlists, compare peers, and value any stock.
No credit card required
CRSP - Crispr Therapeutics AG (CRSP) has a free cash flow of -$401.18M, down 139.1% over the past year and down 7.5% per year over the past five years.
FCF TTM
-$401.18M
FCF Margin
-9777.63%
FCF Yield
-8.67%
5Y CAGR
-7.50%
| Year | Free Cash Flow | Change |
|---|---|---|
| 2025 | -$345.93M | -139.11% |
| 2024 | -$144.68M | +46.39% |
| 2023 | -$269.85M | +49.37% |
| 2022 | -$532.93M | -216.55% |
| 2021 | $457.27M | +278.12% |
| 2020 | -$256.72M | -613.52% |
| 2019 | $49.99M | +150.49% |
| 2018 | -$99.01M | -27.08% |
| 2017 | -$77.91M | - |
| Quarter | Free Cash Flow | Change |
|---|---|---|
| Q1 2026 | -$109.40M | -17.55% |
| Q4 2025 | -$93.07M | -9.87% |
| Q3 2025 | -$84.71M | +25.69% |
| Q2 2025 | -$114.00M | -110.51% |
| Q1 2025 | -$54.15M | -7.69% |
| Q4 2024 | -$50.28M | +53.06% |
| Q3 2024 | -$107.13M | -11.26% |
| Q2 2024 | -$96.29M | -188.31% |
| Q1 2024 | $109.03M | +212.62% |
| Q4 2023 | -$96.81M | -130.65% |
| Q3 2023 | -$41.97M | +69.32% |
| Q2 2023 | -$136.80M | -2483.28% |
| Q1 2023 | $5.74M | +104.80% |
| Q4 2022 | -$119.52M | -7.45% |
| Q3 2022 | -$111.23M | +26.62% |
| Q2 2022 | -$151.59M | -0.66% |
| Q1 2022 | -$150.59M | -58.15% |
| Q4 2021 | -$95.22M | +19.56% |
| Q3 2021 | -$118.38M | -115.20% |
| Q2 2021 | $778.55M | +822.98% |
| Q1 2021 | -$107.69M | -23.14% |
| Q4 2020 | -$87.45M | -7.67% |
| Q3 2020 | -$81.22M | -147.00% |
| Q2 2020 | -$32.88M | +40.39% |
| Q1 2020 | -$55.17M | -2375.83% |
| Q4 2019 | $2.42M | -98.15% |
| Q3 2019 | $130.96M | +439.66% |
| Q2 2019 | -$38.56M | +14.00% |
| Q1 2019 | -$44.83M | -52.64% |
| Q4 2018 | -$29.37M | -42.18% |
| Q3 2018 | -$20.66M | +19.73% |
| Q2 2018 | -$25.74M | -10.73% |
| Q1 2018 | -$23.24M | -54.47% |
| Q4 2017 | -$15.05M | +20.23% |
| Q3 2017 | -$18.86M | -9.00% |
| Q2 2017 | -$17.30M | +35.18% |
| Q1 2017 | -$26.70M | -35.90% |
| Q4 2016 | -$19.64M | -42.50% |
| Q3 2016 | -$13.79M | +5.91% |
| Q2 2016 | -$14.65M | - |
Free cash flow (FCF) is the cash left after a company covers its operating expenses and capital expenditures. It is the money available to repay debt, buy back shares, pay dividends, or reinvest — making it one of the clearest measures of financial strength.